Lauren Dembeck, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/

All articles by Lauren Dembeck, PhD

Multiple Myeloma

Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies

Lauren Dembeck, PhD

May 26, 2020

Novel treatment options are needed to improve outcomes for patients with TP53-mutated myeloid neoplasms.

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic im

Multiple Myeloma

Prognostic Value of Immunomodulator in Higher-Risk Myelodysplastic Syndromes Treated With Azacitidine

Lauren Dembeck, PhD

May 26, 2020

Immunomodulator indoleamine-2,3-dioxygenase may be a promising predictor and therapeutic target for patients with higher-risk myelodysplastic syndromes.

Hematologic Cancers

Venous Thromboembolism vs Major Bleeding: Case Fatality Rates of Patients With Cancer Receiving Anticoagulation

Lauren Dembeck, PhD

May 4, 2020

Case fatality rates may vary among cancer patients with VTE or major bleeding who receive anticoagulant treatments.

Chronic Lymphocytic Leukemia

Keratinocyte Carcinoma Risk Factors in Allogeneic Hematopoietic Cell Transplant Recipients

Lauren Dembeck, PhD

April 22, 2020

Although allogeneic HCT is associated with increased risk for keratinocyte carcinoma, the magnitude of risk linked to certain patient characteristics is still unknown.

Hematologic Cancers

Apixaban Noninferior to Dalteparin for Treatment of Cancer-Associated Venous Thromboembolism

Lauren Dembeck, PhD

April 20, 2020

Oral apixaban is noninferior to subcutaneous dalteparin for the treatment of cancer-linked VTE without increasing the risk of major bleeding.

Chronic Lymphocytic Leukemia

New Prognostic Score Predicts Likelihood of First Treatment Required for Early-Stage Chronic Lymphocytic Leukemia

Lauren Dembeck, PhD

April 20, 2020

A newly developed international prognostic score may be a useful clinical management tool to predict the likelihood of required treatment for patients with early-stage CLL.

Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.

Hematologic Cancers

Real-World Trends in the Assessment of Minimum Residual Disease in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma

Lauren Dembeck, PhD

April 6, 2020

In recent years, the NCCN has updated its clinical practice guidelines to include MRD assessment for MM, ALL, and CLL.

The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.

Hematologic Cancers

Is Tisagenlecleucel for Relapsed Pediatric Acute Lymphoblastic Leukemia Cost-Effective?

Lauren Dembeck, PhD

February 11, 2020

Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.

Lymphoma

Brentuximab Vedotin May Improve Survival in Stage III/IV Classical Hodgkin Lymphoma

Lauren Dembeck, PhD

February 11, 2020

Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.

Gastrointestinal Cancers

Collagenolytic Microbes Associated With a Western Diet May Promote Tumor Formation After Colorectal Surgery

Lauren Dembeck, PhD

February 6, 2020

A mechanism was identified through which a Western diet and antibiotic use may be able to promote tumorigenesis by colon cancer cells after curative resection.

Next post in Gastrointestinal Cancers